The use of Cytokeratin-18 and Interleukin-6
as Diagnostic Markers for Nonalcoholic Fatty Liver Disease
Versandkostenfrei!
Versandfertig in 6-10 Tagen
16,99 €
inkl. MwSt.
PAYBACK Punkte
8 °P sammeln!
Non-alcoholic Fatty Liver disease is the one of most common liver disease in the world, which is defined as the accumulation of fat 5% of liver weight. Presentation of the disease ranges from Simple Steatosis to Non-alcoholic Steatohepatitis, which is a progressive form that may lead to fibrosis, cirrhosis and ultimately hepatocellular carcinoma. Nonalcoholic Fatty Liver Disease is not a single disease, diagnosed by non-invasive biomarkers, imaging techniques and liver biopsy; non-invasive serum markers have been used in the assessment of Non-alcoholic Steatohepatitis, ranging from hepatocyte ...
Non-alcoholic Fatty Liver disease is the one of most common liver disease in the world, which is defined as the accumulation of fat 5% of liver weight. Presentation of the disease ranges from Simple Steatosis to Non-alcoholic Steatohepatitis, which is a progressive form that may lead to fibrosis, cirrhosis and ultimately hepatocellular carcinoma. Nonalcoholic Fatty Liver Disease is not a single disease, diagnosed by non-invasive biomarkers, imaging techniques and liver biopsy; non-invasive serum markers have been used in the assessment of Non-alcoholic Steatohepatitis, ranging from hepatocyte apoptosis by-product cytokeratin-18 fragments, liver biochemical profile serum such as alanine aminotransferase, aspartate aminotransferase, and nonspecific markers of systemic inflammation, such as interleukin-6.
Andere Kunden interessierten sich für
